Abstract:Cardiovascular diseases are the most common cause of death globally. Accurately modeling cardiac homeostasis, dysfunction, and drug response lies at the heart of cardiac research. Adult human primary cardiomyocytes (hPCMs) are a promising cellular model, but unstable isolation efficiency and quality, rapid cell death in culture, and unknown response to cryopreservation prevent them from becoming a reliable and flexible in vitro cardiac model. Combing the use of a reversible inhibitor of myosin II ATPase, (-)-blebbistatin (Bleb), and multiple optimization steps of the isolation procedure, we achieved a 2.74-fold increase in cell viability over traditional methods, accompanied by better cellular morphology, minimally perturbed gene expression, intact electrophysiology, and normal neurohormonal signaling. Further optimization of culture conditions established a method that was capable of maintaining optimal cell viability, morphology, and mitochondrial respiration for at least 7 days. Most importantly, we successfully cryopreserved hPCMs, which were structurally, molecularly, and functionally intact after undergoing the freeze-thaw cycle. hPCMs demonstrated greater sensitivity towards a set of cardiotoxic drugs, compared to human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Further dissection of cardiomyocyte drug response at both the population and single-cell transcriptomic level revealed that hPCM responses were more pronouncedly enriched in cardiac function, whereas hiPSC-CMs responses reflected cardiac development. Together, we established a full set of methodologies for the efficient isolation and prolonged maintenance of functional primary adult human cardiomyocytes in vitro, unlocking their potential as a cellular model for cardiovascular research, drug discovery, and safety pharmacology.

Requirements for human cardiomyocytes

Requirements for human haematopoietic stem/progenitor cells

Requirements for human embryonic stem cells

Requirements for human‐induced pluripotent stem cells

Requirments for primary human hepatocyte

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

General requirements for stem cells

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Engineering Human Ventricular Heart Muscles Based on a Highly Efficient System for Purification of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes

General requirements for the production of extracellular vesicles derived from human stem cells

Human midbrain dopaminergic progenitors

Standards of clinical-grade mesenchymal stromal cell preparation and quality control (2020 China Version)

Technical Specifications for Ethics Review of Human Stem Cell Research

Requirements for human natural killer cells

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Requirements for Human Mesenchymal Stem Cell‐derived Small Extracellular Vesicles

Requirements for human pluripotent stem cell derived small extracellular vesicles

Generation of Clinical-Grade Functional Cardiomyocytes from Human Embryonic Stem Cells in Chemically Defined Conditions

Engineering the maturation of stem cell-derived cardiomyocytes

Functional isolation, culture and cryopreservation of adult human primary cardiomyocytes

Cardiomyocyte Maturation–the Road is Not Obstructed